You are here: Industry Insights > liver cancer treatment

News List

Ally Bridge, LifeTech Scientific, Quantum Surgical unite for liver cancer treatment biospectrumasia
April 09, 2019
Ally Bridge, LifeTech Scientific, Quantum Surgical unite for liver cancer treatment
Lucence Diagnostics to Develop AI Tools for Liver Cancer Treatment en-cphi.cn
March 12, 2019
Lucence Diagnostics, a genomic medicine company focused on personalizing cancer care, today announced a new project to develop AI algorithms for improving diagnosis and treatment of liver cancer.
Eisai's Lenvima gets nod in China for liver cancer treatment biospectrumasia
September 07, 2018
HBV is considered to be a negative predictor of tumor response to existing drug therapies.
Everest Medicines acquires rights to Novartis liver cancer treatment biospectrumasia
June 28, 2018
FGF401 is being evaluated in Phase I/II clinical trials across the U.S., Europe and Asia as a potential new treatment for hepatocellular carcinoma.
Singapore to boost liver cancer treatment biospectrumasia
May 03, 2018
The programme will use Samsung Medical Centre's robotic Avatar Platform, which allows hundreds of sets of cells to be screened at the same time.
Rexahn, Haichang collaborate for developing liver cancer treatment biospectrumasia
February 11, 2018
Any clinical trials conducted by Haichang will be designed to meet both U.S. and Chinese regulatory requirements.
FDA Accepts Supplemental NDA for Lenvatinib as Liver Cancer Treatment americanpharmaceuticacreview
September 28, 2017
There is no guarantee that any investigational uses of such FDA-approved product will gain FDA approval.
FDA expands approved use of Bayer’s liver cancer treatment europeanpharmaceuticalreview
May 03, 2017
The US Food and Drug Administration (FDA) has expanded the approved use of Bayer‘s Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.
FDA grants priority review for Bayer’s liver cancer treatment europeanpharmaceuticalreview
January 05, 2017
The US Food and Drug Administration (FDA) has granted priority review status for the supplemental new drug application for Stivarga (regorafenib, Bayer), as a second line systemic treatment of patients with hepatocellular carcinoma (HCC) in the US.
FDA awards priority review to Bayer's filing for Stivarga as second-line liver cancer treatment firstwordpharma
January 05, 2017
Bayer on Wednesday said the FDA granted priority review to an application seeking approval of Stivarga (regorafenib) for the second-line treatment of patients with hepatocellular carcinoma (HCC).